Influenza Immunisation
14
0
0
11
Key Insights
Highlights
Success Rate
79% trial completion
Published Results
12 trials with published results (86%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
21.4%
3 terminated out of 14 trials
78.6%
-8.0% vs benchmark
29%
4 trials in Phase 3/4
109%
12 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 11 completed trials
Clinical Trials (14)
Age and Response to Flu Vaccines
Flublok or Fluzone With Advax-CpG55.2 or AF03
Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects
Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers
Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination
Development of Childhood Anti-Influenza Immunity
H3N2 M2SR in Pediatric Population
2013/2017 H7N9 Prime-Boost Interval
2017 A/H7N9 IIV Revaccination
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4
Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine
H5N1 With or Without Topical Aldara in Healthy Adults